Wells Fargo’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-21,110
| Closed | -$401K | – | 6900 |
|
|
2019
Q1 | $401K | Sell |
21,110
-1,159
| -5% | -$18.8K | ﹤0.01% | 4461 |
|
|
2018
Q4 | $300K | Buy |
22,269
+19,069
| +596% | +$213K | ﹤0.01% | 4675 |
|
|
2018
Q3 | $36K | Buy |
+3,200
| New | +$32K | ﹤0.01% | 5703 |
|
|
2017
Q1 | – | Sell |
-16,024
| Closed | -$78K | – | 6782 |
|
|
2016
Q4 | $78K | Hold |
16,024
| – | – | ﹤0.01% | 5255 |
|
|
2016
Q3 | $79K | Hold |
16,024
| – | – | ﹤0.01% | 5054 |
|
|
2016
Q2 | $82K | Sell |
16,024
-1,285
| -7% | -$6.92K | ﹤0.01% | 4948 |
|
|
2016
Q1 | $99K | Buy |
17,309
+419
| +2% | +$2.93K | ﹤0.01% | 4841 |
|
|
2015
Q4 | $175K | Buy |
16,890
+414
| +3% | +$5.62K | ﹤0.01% | 4540 |
|
|
2015
Q3 | $304K | Buy |
16,476
+197
| +1% | +$3.8K | ﹤0.01% | 4236 |
|
|
2015
Q2 | $318K | Buy |
16,279
+14,466
| +798% | +$256K | ﹤0.01% | 4343 |
|
|
2015
Q1 | $32K | Buy |
1,813
+783
| +76% | +$13.2K | ﹤0.01% | 5204 |
|
|
2014
Q4 | $16K | Buy |
1,030
+8
| +0.8% | +$107 | ﹤0.01% | 5466 |
|
|
2014
Q3 | $13K | Sell |
1,022
-477
| -32% | -$6.8K | ﹤0.01% | 5500 |
|
|
2014
Q2 | $23K | Buy |
1,499
+499
| +50% | +$7.34K | ﹤0.01% | 5328 |
|
|
2014
Q1 | $13K | Sell |
1,000
-8,189
| -89% | -$128K | ﹤0.01% | 5344 |
|
|
2013
Q4 | $148K | Buy |
9,189
+8,689
| +1,738% | +$138K | ﹤0.01% | 4380 |
|
|
2013
Q3 | $8K | Sell |
500
-700
| -58% | -$10.3K | ﹤0.01% | 5193 |
|
|
2013
Q2 | $12K | Buy |
+1,200
| New | +$12.6K | ﹤0.01% | 5029 |
|
Other funds holding OSIR
Wells Fargo's OSIR Position: Q2 2019 in Review
Wells Fargo sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 21,110 shares — an estimated $401K sold.
Wells Fargo first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $401K in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Wells Fargo reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Wells Fargo sold 21,110 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $401K.
- Wells Fargo first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- Wells Fargo's Osiris Therapeutics, Inc. Common Stock position peaked at $401K in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Wells Fargo's 13F filing for Q2 2019, filed 6 Aug 2019.